Nemes Rush Group’s Neurocrine Biosciences NBIX Stock Holding History

Nemes Rush Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$142	–	1003
2025 Q4	$142	Buy	+1	New	+$145	﹤0.01%	950

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nemes Rush Group's NBIX Position: Q1 2026 in Review

Nemes Rush Group sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 1 share — an estimated $142 sold.

Nemes Rush Group first reported a position in NBIX in Q4 2025 and held it in 1 quarter. The position peaked at $142 in Q4 2025. 699 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Nemes Rush Group reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Nemes Rush Group sold 1 Neurocrine Biosciences share in Q1 2026, an estimated $142.
Nemes Rush Group first reported a position in Neurocrine Biosciences in Q4 2025 and held it in 1 quarter.
Nemes Rush Group's Neurocrine Biosciences position peaked at $142 in Q4 2025.
699 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.